Avisa Diagnostics Inc. operates a clinical-stage medical device company. It is developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company offers clinical proof-of-concept through tri...
Avisa Diagnostics reported revenue of $277,830 for fiscal year 2020, and net income of -$715,762.
Figures from company filings; latest fiscal year ended December 31, 2020.
No profile data available.